{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:58:19Z","timestamp":1791921499428,"version":"4.3.4"},"reference-count":179,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,1,12]],"date-time":"2020-01-12T00:00:00Z","timestamp":1578787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Washington University Institute of Clinical and Translational Sciences","award":["UL1TR002345"],"award-info":[{"award-number":["UL1TR002345"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The treatment of invasive fungal infections remains challenging due to limitations in currently available antifungal therapies including toxicity, interactions, restricted routes of administration, and drug resistance. This review focuses on novel therapies in clinical development, including drugs and a device. These drugs have novel mechanisms of action to overcome resistance, and some offer new formulations providing distinct advantages over current therapies to improve safety profiles and reduce interactions. Among agents that target the cell wall, 2 glucan synthesis inhibitors are discussed (rezafungin and ibrexafungerp), as well as fosmanogepix and nikkomycin Z. Agents that target the cell membrane include 3 fourth-generation azoles, oral encochleated amphotericin B, and aureobasidin A. Among agents with intracellular targets, we will review olorofim, VL-2397, T-2307, AR-12, and MGCD290. In addition, we will describe neurapheresis, a device used as adjunctive therapy for cryptococcosis. With a field full of novel treatments for fungal infections, the future looks promising.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa016","type":"journal-article","created":{"date-parts":[[2020,1,12]],"date-time":"2020-01-12T12:26:21Z","timestamp":1578831981000},"source":"Crossref","is-referenced-by-count":192,"title":["Hope on the Horizon: Novel Fungal Treatments in Development"],"prefix":"10.1093","volume":"7","author":[{"given":"Adriana M","family":"Rauseo","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariella","family":"Coler-Reilly","sequence":"first","affiliation":[{"name":"Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Larson","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7612-4710","authenticated-orcid":false,"given":"Andrej","family":"Spec","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,12]]},"reference":[{"key":"2020021921303983100_CIT0001","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1126\/science.aaa6097","article-title":"Infectious disease. How to bolster the antifungal pipeline","volume":"347","author":"Denning","year":"2015","journal-title":"Science"},{"key":"2020021921303983100_CIT0002","doi-asserted-by":"crossref","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci Transl Med"},{"key":"2020021921303983100_CIT0003","first-page":"64","article-title":"Invasive fungal infections: a comprehensive review","volume":"1","author":"Ramana","year":"2013","journal-title":"Am J Infect Dis Microbiol"},{"key":"2020021921303983100_CIT0004","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s40265-017-0805-2","article-title":"Drugs in clinical development for fungal infections","volume":"77","author":"Gonzalez-Lara","year":"2017","journal-title":"Drugs"},{"key":"2020021921303983100_CIT0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10096-013-1944-3","article-title":"Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species","volume":"33","author":"Drgona","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020021921303983100_CIT0006","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S1473-3099(18)30373-6","article-title":"Histoplasmosis dethrones tuberculosis in Latin America","volume":"18","author":"Pasqualotto","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2020021921303983100_CIT0007","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1473-3099(18)30354-2","article-title":"Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: a modelling study","volume":"18","author":"Adenis","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2020021921303983100_CIT0008","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-6515-1_5","article-title":"Systemic antifungal agents: current status and projected future developments","volume-title":"Human Fungal Pathogen Identification. Methods in Molecular Biology","author":"Seyedmousavi","year":"2017"},{"key":"2020021921303983100_CIT0009","article-title":"Novel antifungal agents: a patent review (2013 - present)","author":"Castelli","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"2020021921303983100_CIT0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/cix257","article-title":"Intercountry transfer of triazole-resistant Aspergillus fumigatus on plant bulbs","volume":"65","author":"Dunne","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020021921303983100_CIT0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mmy\/myy054","article-title":"Candida auris: the recent emergence of a multidrug-resistant fungal pathogen","volume":"57","author":"Forsberg","year":"2019","journal-title":"Med Mycol"},{"key":"2020021921303983100_CIT0012","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1093\/infdis\/jix210","article-title":"Azole-resistant Aspergillosis: epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Chowdhary","year":"2017","journal-title":"J Infect Dis"},{"key":"2020021921303983100_CIT0013","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020021921303983100_CIT0014","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/21505594.2016.1257457","article-title":"New facets of antifungal therapy","volume":"8","author":"Chang","year":"2017","journal-title":"Virulence"},{"key":"2020021921303983100_CIT0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkg117","article-title":"Caspofungin: the first representative of a new antifungal class","volume":"51","author":"Letscher-Bru","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0016","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/mmy\/myz012","article-title":"Antifungal drugs: what brings the future?","volume":"57","author":"Van Daele","year":"2019","journal-title":"Med Mycol"},{"key":"2020021921303983100_CIT0017","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The antifungal pipeline: a reality check","volume":"16","author":"Perfect","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2020021921303983100_CIT0018","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ja.2016.89","article-title":"CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility","volume":"70","author":"Krishnan","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"2020021921303983100_CIT0019","doi-asserted-by":"crossref","first-page":"e00758-17","DOI":"10.1128\/AAC.00758-17","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","author":"Lakota","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0020","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/jac\/dkw214","article-title":"Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates","volume":"71","author":"Pfaller","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0021","doi-asserted-by":"crossref","first-page":"e01627-16","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0022","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0023","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1182\/blood.V128.22.3396.3396","article-title":"Efficacy of CD101, a novel echinocandin, in prevention of pneumocystis pneumonia (PCP): thwarting the biphasic life cycle of pneumocystis","volume":"128","author":"Cushion","year":"2016","journal-title":"Blood"},{"key":"2020021921303983100_CIT0024","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1021\/acs.jmedchem.7b01413","article-title":"Emerging new targets for the treatment of resistant fungal infections","volume":"61","author":"Liu","year":"2018","journal-title":"J Med Chem"},{"key":"2020021921303983100_CIT0025","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2017.03.028","article-title":"CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program","volume":"50","author":"Pfaller","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2020021921303983100_CIT0026","doi-asserted-by":"crossref","first-page":"e02614-17","DOI":"10.1128\/AAC.02603-17","article-title":"Population pharmacokinetic analyses for rezafungin (CD101) efficacy using phase 1 data","volume":"62","author":"Lakota","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0027","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1128\/AAC.00620-16","article-title":"Characterization of in vitro resistance development to the novel echinocandin CD101 in Candida species","volume":"60","author":"Locke","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0028","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2018.02.021","article-title":"Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method","volume":"24","author":"Arendrup","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2020021921303983100_CIT0029","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/jac\/dky280","article-title":"Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0030","doi-asserted-by":"crossref","first-page":"e02603-17","DOI":"10.1128\/AAC.02603-17","article-title":"Population pharmacokinetic analyses for rezafungin (CD101) efficacy using phase 1 data","volume":"62","author":"Lakota","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0031","doi-asserted-by":"crossref","first-page":"e01541-16","DOI":"10.1128\/AAC.01541-16","article-title":"Structure-activity relationships of a series of echinocandins and the discovery of CD101, a highly stable and soluble echinocandin with distinctive pharmacokinetic properties","volume":"61","author":"James","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0032","doi-asserted-by":"crossref","first-page":"e02154-17","DOI":"10.1128\/AAC.02154-17","article-title":"Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0033","doi-asserted-by":"crossref","first-page":"e01572-18","DOI":"10.1128\/AAC.01572-18","article-title":"Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0034","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/jac\/dky153","article-title":"Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model","volume":"73","author":"Hager","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0035","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1182\/blood.V128.22.3400.3400","article-title":"Efficacy of CD101, a novel echinocandin, in mouse models of aspergillosis and azole-resistant disseminated candidiasis","volume":"128","author":"Ong","year":"2016","journal-title":"Blood"},{"key":"2020021921303983100_CIT0036","doi-asserted-by":"crossref","first-page":"e01009-17","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0037","volume-title":"Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin.","author":"Cidara Therapeutics","year":"2018"},{"key":"2020021921303983100_CIT0038","volume-title":"Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC","author":"Cidara Therapeutics","year":"2017"},{"key":"2020021921303983100_CIT0039","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/LGT.0000000000000473","article-title":"CD101 topical compared with oral fluconazole for acute vulvovaginal candidiasis: a randomized controlled trial","volume":"23","author":"Nyirjesy","year":"2019","journal-title":"J Low Genit Tract Dis"},{"key":"2020021921303983100_CIT0040","doi-asserted-by":"crossref","first-page":"e02068-16","DOI":"10.1128\/AAC.02068-16","article-title":"Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis","volume":"61","author":"Wring","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0041","doi-asserted-by":"crossref","first-page":"e01102-17","DOI":"10.1128\/AAC.01102-17","article-title":"Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0042","doi-asserted-by":"crossref","unstructured":"Lee A , PrideauxB, LeeM, et al. Penetration of Ibrexafungerp (formerly SCY-078) versus micafungin at the site of infection in an intra-abdominal candidiasis mouse model. ECCMID (Amsterdam, Netherlands). 13\u201316 April 2019.","DOI":"10.1128\/AAC.02268-19"},{"key":"2020021921303983100_CIT0043","doi-asserted-by":"crossref","first-page":"e02611-18","DOI":"10.1128\/AAC.02611-18","article-title":"A novel 1,3-Beta-d-glucan inhibitor, Ibrexafungerp (formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis","volume":"63","author":"Larkin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0044","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/jcph.1146","article-title":"Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug-drug interactions","volume":"58","author":"Wring","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2020021921303983100_CIT0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cpdd.588","article-title":"Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus","volume":"8","author":"Wring","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2020021921303983100_CIT0046","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/jac\/dks466","article-title":"Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)","volume":"68","author":"Pfaller","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0047","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","article-title":"In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods","volume":"57","author":"Pfaller","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0048","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates","volume":"58","author":"Jim\u00e9nez-Ortigosa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0049","doi-asserted-by":"crossref","first-page":"e02396-16","DOI":"10.1128\/AAC.02396-16","article-title":"The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation","volume":"61","author":"Larkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0050","doi-asserted-by":"crossref","first-page":"e00435-17","DOI":"10.1128\/AAC.00435-17","article-title":"In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris","volume":"61","author":"Berkow","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0051","doi-asserted-by":"crossref","first-page":"e00161-17","DOI":"10.1128\/AAC.00161-17","article-title":"Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0052","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00234-15","article-title":"Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0053","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jac\/dkx422","article-title":"Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0054","unstructured":"Cushion M , AshbaughA, Borroto-EsodaK, et al SCY-078 demonstrates antifungal activity against pneumocystis in a prophylactic murine model of pneumocystis pneumonia. ECCMID (Madrid, Spain). 21\u201324 April 2018."},{"key":"2020021921303983100_CIT0055","unstructured":"Barat S , Borroto-EsodaK, AshbaughA, CushionMT. Efficacy of Ibrexafungerp (formerly SCY-078) against pneumocystis pneumonia in a murine therapeutic model. ECCMID (Amsterdam, Netherlands). 13\u201316 April 2019."},{"key":"2020021921303983100_CIT0056","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ajog.2017.08.099","article-title":"A multicenter, randomized, evaluator blinded, active-controlled study to evaluate the safety and efficacy of oral SCY-078 vs. oral fluconazole in 96 subjects with moderate to severe vulvovaginal candidiasis","volume":"217","author":"Helou","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"2020021921303983100_CIT0057","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/jac\/dkz277","article-title":"MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis","volume":"74","author":"Spec","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0058","volume-title":"Ibrexafungerp (formerly SCY-078): An Innovative Antifungal","author":"SCYNEXIS I"},{"key":"2020021921303983100_CIT0059","unstructured":"Juneja D , SinghO, TaraiB, Angulo GonzalezD. Successful treatment of two patients with Candida auris candidemia with the investigational agent, oral Ibrexafungerp (formerly SCY-078) from the CARES study. ECCMID (Amsterdam, Netherlands). 13\u201316 April 2019."},{"key":"2020021921303983100_CIT0060","unstructured":"Cornely OA , Ostrosky-ZeichnerL, MillerR, et al. Favorable response to oral Ibrexafungerp (formerly SCY-078) in patients with refractory fungal diseases, interim analysis by pathogen from a phase 3 open-label study (FURI). ECCMID (Amsterdam, Netherlands). 13 -16 April 2019."},{"key":"2020021921303983100_CIT0061","unstructured":"K\u00f6hler P , CornelyOA, Angulo GonzalezD. Favourable clinical outcome of two patients with Candida spp spondylodiscitis treated with oral Ibrexafungerp (formerly SCY-078) from the FURI study. ECCMID (Amsterdam, Netherlands). 13 -16 April 2019."},{"key":"2020021921303983100_CIT0062","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0063","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0064","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diagmicrobio.2011.05.001","article-title":"In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method","volume":"71","author":"Pfaller","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020021921303983100_CIT0065","doi-asserted-by":"crossref","first-page":"e00523-18","DOI":"10.1128\/AAC.00523-18","article-title":"In vitro and in vivo evaluation of APX001A\/APX001 and other Gwt1 inhibitors against Cryptococcus","volume":"62","author":"Shaw","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01715-18","article-title":"APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis pneumonia","volume":"63","author":"Viriyakosol","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0067","doi-asserted-by":"crossref","first-page":"e02319-17","DOI":"10.1128\/AAC.02319-17","article-title":"In vitro and in vivo evaluation of the antifungal activity of APX001A\/APX001 against Candida auris","volume":"62","author":"Hager","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0068","first-page":"1","article-title":"In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated candidiasis mouse model","volume":"62","author":"Zhao","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0069","first-page":"214","article-title":"EUCAST susceptibility testing of APX001A: MIC data for contemporary clinical blood stream isolates","volume":"60","author":"J\u00f8rgensen","year":"2017","journal-title":"Mycoses"},{"key":"2020021921303983100_CIT0070","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.00570-11","article-title":"In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods","volume":"55","author":"Pfaller","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0071","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1128\/AAC.05414-11","article-title":"Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods","volume":"56","author":"Castanheira","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0072","doi-asserted-by":"crossref","first-page":"e00425-18","DOI":"10.1128\/AAC.00425-18","article-title":"Significantly improved pharmacokinetics enhances in vivo efficacy of APX001 against echinocandin-and multidrug-resistant Candida isolates in a mouse model of invasive candidiasis","volume":"62","author":"Zhao","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0073","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1128\/AAC.00366-11","article-title":"Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis","volume":"55","author":"Hata","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0074","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1128\/AAC.03944-14","article-title":"The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans","volume":"59","author":"Wiederhold","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0075","doi-asserted-by":"crossref","first-page":"e02372-18","DOI":"10.1128\/AAC.02372-18","article-title":"APX001 pharmacokinetic\/pharmacodynamic target determination against Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis","volume":"63","author":"Zhao","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0076","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1093\/ofid\/ofx163.1209","article-title":"Absorption, distribution, and excretion of 14C-APX001 after single-dose administration to rats and monkeys","volume":"4","author":"Mansbach","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020021921303983100_CIT0077","doi-asserted-by":"crossref","first-page":"S526","DOI":"10.1093\/ofid\/ofx163.1370","article-title":"First-in-human study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects","volume":"4","author":"Hodges","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020021921303983100_CIT0078","doi-asserted-by":"crossref","first-page":"S534","DOI":"10.1093\/ofid\/ofx163.1390","article-title":"Phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple oral doses of APX001 and to investigate the effect of food on APX001 bioavailability","volume":"4","author":"Hodges","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020021921303983100_CIT0079","volume-title":"APX001 Fact Sheet","author":"Amplyx"},{"key":"2020021921303983100_CIT0080","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1021\/op3003294","article-title":"A practical and scalable manufacturing process for an anti-fungal agent, Nikkomycin Z","volume":"17","author":"Stenland","year":"2013","journal-title":"Org Process Res Dev"},{"key":"2020021921303983100_CIT0081","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1128\/AAC.44.6.1624-1629.2000","article-title":"Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model","volume":"44","author":"Goldberg","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0082","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.42.9.2371","article-title":"Efficacy of nikkomycin Z in the treatment of murine histoplasmosis","volume":"42","author":"Graybill","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0083","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/AAC.34.4.587","article-title":"Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis","volume":"34","author":"Hector","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0084","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3109\/13693786.2013.770610","article-title":"Efficacy of Nikkomycin Z for respiratory coccidioidomycosis in naturally infected dogs","volume":"51","author":"Shubitz","year":"2013","journal-title":"Med Mycol"},{"key":"2020021921303983100_CIT0085","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1128\/AAC.41.9.2026","article-title":"Efficacy of nikkomycin Z against experimental pulmonary blastomycosis","volume":"41","author":"Clemons","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0086","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1469-0691.2004.00996.x","article-title":"In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus","volume":"10","author":"Ganesan","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"2020021921303983100_CIT0087","doi-asserted-by":"crossref","first-page":"e00619-17","DOI":"10.1128\/AAC.00619-17","article-title":"Effects of Echinocandins in combination with Nikkomycin Z against invasive Candida albicans bloodstream isolates and the fks mutants","volume":"61","author":"Cheung","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0088","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1128\/AAC.43.6.1401","article-title":"In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole","volume":"43","author":"Li","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0089","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/infdis\/jiu029","article-title":"Modeling nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials","volume":"209","author":"Shubitz","year":"2014","journal-title":"J Infect Dis"},{"key":"2020021921303983100_CIT0090","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1128\/AAC.01609-08","article-title":"Pharmacokinetics of nikkomycin Z after single rising oral doses","volume":"53","author":"Nix","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0091","volume-title":"Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment","author":"ClinicalTrials.gov"},{"key":"2020021921303983100_CIT0092","volume-title":"A first-in-class compound, New Mechanism of Action","author":"Valley Fever Solutions"},{"key":"2020021921303983100_CIT0093","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.bmcl.2017.06.037","article-title":"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors","volume":"27","author":"Yates","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"2020021921303983100_CIT0094","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0095","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1128\/AAC.00349-16","article-title":"The investigational drug VT-1129 is a highly potent inhibitor of Cryptococcus species CYP51 but only weakly inhibits the human enzyme","volume":"60","author":"Warrilow","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0096","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1128\/AAC.00593-15","article-title":"Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models","volume":"59","author":"Shubitz","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0097","unstructured":"Long L , IshamN, GhannounM, et al. High in vitro potency of the clinical investigational agent VT-1161 against clinical isolates of Candida spp. 25th ECCMID (Copenhagen, Denmark) , 25\u201328 April 2015."},{"key":"2020021921303983100_CIT0098","doi-asserted-by":"crossref","first-page":"e00333-17","DOI":"10.1128\/AAC.00333-17","article-title":"The Tetrazole VT-1161 Is a potent inhibitor of Trichophyton rubrum through its inhibition of T. rubrum CYP51","volume":"61","author":"Warrilow","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0099","doi-asserted-by":"crossref","first-page":"e01817-16","DOI":"10.1128\/AAC.01817-16","article-title":"Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0100","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.1128\/AAC.01437-15","article-title":"VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection","volume":"59","author":"Gebremariam","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0101","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1128\/AAC.00185-15","article-title":"Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis","volume":"59","author":"Garvey","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0102","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1128\/AAC.04902-14","article-title":"VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model","volume":"59","author":"Garvey","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0103","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1128\/AAC.02770-15","article-title":"The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against Cryptococcus neoformans and Cryptococcus gattii","volume":"60","author":"Lockhart","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0104","first-page":"453","article-title":"Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs","volume":"55","author":"Nielsen","year":"2017","journal-title":"Med Mycol"},{"key":"2020021921303983100_CIT0105","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01071-18","article-title":"The fungal Cyp51 inhibitor VT-1129 is efficacious in an experimental model of cryptococcal meningitis","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0106","doi-asserted-by":"crossref","first-page":"e01315-18","DOI":"10.1128\/AAC.01315-18","article-title":"In vivo efficacy of VT-1129 against experimental cryptococcal meningitis with the use of a loading dose-maintenance dose administration strategy","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0107","doi-asserted-by":"crossref","first-page":"e00570-17","DOI":"10.1128\/AAC.00570-17","article-title":"Crystal structure of the new investigational drug candidate VT-1598 in complex with Aspergillus fumigatus sterol 14\u03b1-demethylase provides insights into its broad-spectrum antifungal activity","volume":"61","author":"Hargrove","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0108","doi-asserted-by":"crossref","first-page":"e02258-17","DOI":"10.1128\/AAC.02258-17","article-title":"The novel fungal Cyp51 inhibitor VT-1598 is efficacious in experimental models of central nervous system coccidioidomycosis caused by Coccidioides posadasii and Coccidioides immitis","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0109","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/jac\/dky170","article-title":"VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice","volume":"73","author":"Break","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0110","doi-asserted-by":"crossref","first-page":"e02233-18","DOI":"10.1128\/AAC.02233-18","article-title":"The fungal Cyp51-specific inhibitor VT-1598 demonstrates in vitro and in vivo activity against Candida auris","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0111","doi-asserted-by":"crossref","first-page":"624.e1","DOI":"10.1016\/j.ajog.2018.03.001","article-title":"A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis","volume":"218","author":"Brand","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"2020021921303983100_CIT0112","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.44.9.2356-2360.2000","article-title":"Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis","volume":"44","author":"Santangelo","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0113","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.44.6.1463-1469.2000","article-title":"Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model","volume":"44","author":"Zarif","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0114","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/pharmaceutics11030099","article-title":"The development of oral amphotericin b to treat systemic fungal and parasitic infections: has the myth been finally realized?","volume":"11","author":"Cuddihy","year":"2019","journal-title":"Pharmaceutics"},{"key":"2020021921303983100_CIT0115","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/jps.10173","article-title":"Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system","volume":"91","author":"Segarra","year":"2002","journal-title":"J Pharm Sci"},{"key":"2020021921303983100_CIT0116","unstructured":"Mannino R , PerlinD. Oral dosing of encochleated amphotericin B (CAmB): rapid drug targeting to infected tissues in MiOral dosing of encochleated amphotericin B (CAmB): rapid drug targeting to infected tissues in mice. ICAAC and ICC (San Diego, CA). 17\u201321 September 2015."},{"key":"2020021921303983100_CIT0117","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.46.8.2704-2707.2002","article-title":"Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis","volume":"46","author":"Delmas","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0118","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/600105","article-title":"Highly effective oral amphotericin B formulation against murine visceral leishmaniasis","volume":"200","author":"Wasan","year":"2009","journal-title":"J Infect Dis"},{"key":"2020021921303983100_CIT0119","doi-asserted-by":"crossref","first-page":"e00724-19","DOI":"10.1128\/mBio.00724-19","article-title":"Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis","volume":"10","author":"Lu","year":"2019","journal-title":"MBio"},{"key":"2020021921303983100_CIT0120","volume-title":"Oral Administration of Amphotericin B (CAmB) in Humans: a Phase I Study of Tolerability and Pharmacokinetics","author":"Biederdorf"},{"key":"2020021921303983100_CIT0121","volume-title":"MAT2203: LNC Formulation of Amphotericin B.","author":"Matinas BioPharma Holdings"},{"key":"2020021921303983100_CIT0122","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1439-0507.2012.02225.x","article-title":"The inhibitory effects of aureobasidin A on Candida planktonic and biofilm cells","volume":"56","author":"Tan","year":"2013","journal-title":"Mycoses"},{"key":"2020021921303983100_CIT0123","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.7164\/antibiotics.46.1414","article-title":"Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic","volume":"46","author":"Takesako","year":"1993","journal-title":"J Antibiot (Tokyo)"},{"key":"2020021921303983100_CIT0124","volume-title":"Takara Bio grants a non-exclusive license of its proprietary antibiotic aureobasidin A-related patents to AureoGen Biosciences for development of novel drugs. News Release.","author":"Takara Bio Inc"},{"key":"2020021921303983100_CIT0125","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/AAC.44.3.651-653.2000","article-title":"Inhibition of inositol phosphorylceramide synthase by aureobasidin A in Candida and Aspergillus species","volume":"44","author":"Zhong","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0126","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pharmthera.2018.10.008","article-title":"Antifungal drugs: new insights in research & development","volume":"195","author":"Moraes Nicola","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2020021921303983100_CIT0127","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2323\/jgam.61.108","article-title":"Characteristics of inositol phosphorylceramide synthase and effects of aureobasidin A on growth and pathogenicity of Botrytis cinerea","volume":"61","author":"Wang","year":"2015","journal-title":"J Gen Appl Microbiol"},{"key":"2020021921303983100_CIT0128","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020021921303983100_CIT0129","doi-asserted-by":"crossref","first-page":"e01157-17","DOI":"10.1128\/mBio.01157-17","article-title":"Pharmacodynamics of the Orotomides against Aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease","volume":"8","author":"Hope","year":"2017","journal-title":"MBio"},{"key":"2020021921303983100_CIT0130","doi-asserted-by":"crossref","first-page":"e00231-18","DOI":"10.1128\/AAC.00231-18","article-title":"Effect of the novel antifungal drug F901318 (olorofim) on growth and viability of Aspergillus fumigatus","volume":"62","author":"Du Pr\u00e9","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0131","unstructured":"Law D , BirchM, OliverJ, et al. Pharmacokinetics of the novel antifungal agent F901318 in mice, rats and cynomolgus monkeys. 55th ICAAC (San Diego, CA). 17\u201321 September 2015."},{"key":"2020021921303983100_CIT0132","unstructured":"Kennedy T , GrahamA, SteinerJ, et al. An open-label study in healthy volunteers to evaluate the potential for cytochrome P450 3A4 inhibition by F901318 using oral midazolam as a probe. ECCMID (Vienna, Austria). 22\u201325 April 2017."},{"key":"2020021921303983100_CIT0133","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/jac\/dkx065","article-title":"Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans","volume":"72","author":"Wiederhold","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0134","first-page":"1050","article-title":"In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi","volume":"56","author":"Biswas","year":"2018","journal-title":"Med Mycol"},{"key":"2020021921303983100_CIT0135","doi-asserted-by":"crossref","first-page":"e01356-18","DOI":"10.1128\/AAC.01356-18","article-title":"Reliable and easy-to-use liquid chromatography-tandem mass spectrometry assay for quantification of olorofim (F901318), a novel antifungal drug, in human plasma and serum","volume":"62","author":"M\u00fcller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0136","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1093\/jac\/dkx177","article-title":"In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates","volume":"72","author":"Buil","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0137","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jac\/dkz078","article-title":"In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0138","doi-asserted-by":"crossref","first-page":"e00487-18","DOI":"10.1128\/AAC.00487-18","article-title":"EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs","volume":"62","author":"J\u00f8rgensen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0139","unstructured":"Beckmann N , BinderU, Lass-Fl\u00f6rlC, et al. Activity of F901318, a member of the new orotomide class of antifungal agents, against clinical Aspergillus isolates from the UK and Austria. 55th ICAAC (San Diego, CA). 17\u201321 September 2015."},{"key":"2020021921303983100_CIT0140","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1093\/jac\/dky329","article-title":"Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei","volume":"73","author":"Lackner","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0141","doi-asserted-by":"crossref","first-page":"e00129-19","DOI":"10.1128\/AAC.00129-19","article-title":"Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. Nidulans, and A. Tanneri in murine models of profound neutropenia and chronic granulomatous disease","volume":"63","author":"Seyedmousavi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0142","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/infdis\/jix479","article-title":"Pharmacodynamics of the novel antifungal agent F901318 for acute sinopulmonary aspergillosis caused by Aspergillus flavus","volume":"217","author":"Negri","year":"2018","journal-title":"J Infect Dis"},{"key":"2020021921303983100_CIT0143","article-title":"Multiple dose pharmacokinetics of an immediate-release tablet formulation of F901318 in healthy male and female subjects","author":"Kennedy"},{"key":"2020021921303983100_CIT0144","volume-title":"F2G expands investor syndicate and progresses Phase IIb study for novel antifungal. F2G News & Publications","author":"F2G"},{"key":"2020021921303983100_CIT0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ja.2016.106","article-title":"Discovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infection","volume":"70","author":"Nakamura","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"2020021921303983100_CIT0146","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ja.2016.107","article-title":"ASP2397: a novel antifungal agent produced by Acremonium persicinum MF-347833","volume":"70","author":"Nakamura","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"2020021921303983100_CIT0147","doi-asserted-by":"crossref","first-page":"e02689-18","DOI":"10.1128\/AAC.02689-18","article-title":"ASP2397 is a novel natural compound that exhibits rapid and potent fungicidal activity against Aspergillus species through a specific transporter","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0148","doi-asserted-by":"crossref","first-page":"e00163-19","DOI":"10.1128\/AAC.00163-19","article-title":"Population pharmacokinetic modeling of VL-2397, a novel systemic antifungal agent: analysis of a single- and multiple-ascending-dose study in healthy subjects","volume":"63","author":"Kovanda","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0149","unstructured":"Wiederhold N , NajvarL, JaramilloR, et al. The novel antifungal VL -2397 demonstrates efficacy in an in vivo model of invasive candidiasis caused by wild-type and multi-drug resistant Candida glabrata. ASM Microbe, New Orleans, LA,1\u20135 June 2017."},{"key":"2020021921303983100_CIT0150","unstructured":"Mammen M , ArmasD, SmithL, et al. Phase 1 safety and pharmacokinetics study of VL-2397, a novel antifungal agent. ASM Microbe; 2017."},{"key":"2020021921303983100_CIT0151","volume-title":"Development of VL-2397 as an Antifungal Drug Candidate to Treat Invasive Fungal Infections","author":"Vical Pharmaceutics"},{"key":"2020021921303983100_CIT0152","volume-title":"VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults","author":"ClinicalTrials.gov"},{"key":"2020021921303983100_CIT0153","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/jac\/dkq177","article-title":"Uptake of T-2307, a novel arylamidine, in Candida albicans","volume":"65","author":"Nishikawa","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0154","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1128\/AAC.05954-11","article-title":"T-2307 causes collapse of mitochondrial membrane potential in yeast","volume":"56","author":"Shibata","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0155","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jac\/dkw095","article-title":"T-2307, a novel arylamidine, is transported into Candida albicans by a high-affinity spermine and spermidine carrier regulated by Agp2","volume":"71","author":"Nishikawa","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0156","doi-asserted-by":"crossref","first-page":"e00374-19","DOI":"10.1128\/AAC.00374-19","article-title":"The novel arylamidine T-2307 selectively disrupts yeast mitochondrial function by inhibiting respiratory chain complexes","volume":"63","author":"Yamashita","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0157","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.01159-07","article-title":"In vitro and in vivo antifungal activities of T-2307, a novel arylamidine","volume":"52","author":"Mitsuyama","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0158","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/jac\/dkx020","article-title":"In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen","volume":"72","author":"Nishikawa","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0159","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jac\/dkv398","article-title":"The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata","volume":"71","author":"Wiederhold","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020021921303983100_CIT0160","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1128\/AAC.04228-14","article-title":"The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans","volume":"59","author":"Wiederhold","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0161","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1128\/AAC.00355-10","article-title":"T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena","volume":"54","author":"Yamada","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0162","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/acsinfecdis.5b00134","article-title":"Antitumor\/antifungal celecoxib derivative AR-12 is a non-nucleoside inhibitor of the ANL-family adenylating enzyme acetyl CoA synthetase","volume":"2","author":"Koselny","year":"2016","journal-title":"ACS Infect Dis"},{"key":"2020021921303983100_CIT0163","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/cb100399x","article-title":"Identification, in vitro activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal molecules","volume":"6","author":"Baxter","year":"2011","journal-title":"ACS Chem Biol"},{"key":"2020021921303983100_CIT0164","doi-asserted-by":"crossref","first-page":"7115","DOI":"10.1128\/AAC.01061-16","article-title":"The celecoxib derivative AR-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis","volume":"60","author":"Koselny","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021921303983100_CIT0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1128\/EC.00235-12","article-title":"Cryptococcus neoformans phosphoinositide-dependent kinase 1 (PDK1) ortholog is required for stress tolerance and survival in murine phagocytes","volume":"12","author":"Chabrier-Rosell\u00f3","year":"2013","journal-title":"Eukaryot Cell"},{"key":"2020021921303983100_CIT0166","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1208\/s12249-017-0752-y","article-title":"Trans-ungual delivery of AR-12, a novel antifungal drug","volume":"18","author":"Kushwaha","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"2020021921303983100_CIT0167","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fmicb.2015.00096","article-title":"Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis","volume":"6","author":"Lamoth","year":"2015","journal-title":"Front Microbiol"},{"key":"2020021921303983100_CIT0168","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.diagmicrobio.2014.11.008","article-title":"In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species","volume":"81","author":"Pfaller","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020021921303983100_CIT0169","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1128\/JCM.00618-09","article-title":"Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2020021921303983100_CIT0170","volume-title":"MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis","author":"ClinicalTrials.gov"},{"key":"2020021921303983100_CIT0171","volume-title":"MethylGene Reports Results of Phase II Trial of MGCD290","author":"MethylGene"},{"key":"2020021921303983100_CIT0172","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/infdis\/jiy286","article-title":"Novel treatment of cryptococcal meningitis via neurapheresis therapy","volume":"218","author":"Smilnak","year":"2018","journal-title":"J Infect Dis"},{"key":"2020021921303983100_CIT0173","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N Engl J Med"},{"key":"2020021921303983100_CIT0174","doi-asserted-by":"crossref","first-page":"E148","DOI":"10.1093\/ons\/opy151","article-title":"Novel dual lumen catheter and filtration device for removal of subarachnoid hemorrhage: first case report","volume":"16","author":"Blackburn","year":"2019","journal-title":"Oper Neurosurg (Hagerstown)"},{"key":"2020021921303983100_CIT0175","unstructured":"Ejikeme T , ChongsathidkietP, BallardC, et al. A Novel Therapeutic Approach for Leptomeningeal Metastases. Mayo Clinic Neuroscience and Oncology Innovation Summit (Orlando, FL). 14-16 December 2017."},{"key":"2020021921303983100_CIT0176","doi-asserted-by":"crossref","unstructured":"Ballard C , AshrafB, EjikemeT, et al. Feasibility of NeurapheresisTM as a therapy for multidrug resistant Gram-negative bacterial meningitis. IDWeek (San Diego, CA). 4\u20138 October 2017.","DOI":"10.1093\/ofid\/ofx163.1233"},{"key":"2020021921303983100_CIT0177","article-title":"The changing","volume-title":"Methods Mol Biol 2017;1508:17\u201365.","author":"Enoch"},{"key":"2020021921303983100_CIT0178","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/01.pra.0000344917.43780.77","article-title":"Medication adherence: a review of the literature and implications for clinical practice","volume":"15","author":"Julius","year":"2009","journal-title":"J Psychiatr Pract"},{"key":"2020021921303983100_CIT0179","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF02850081","article-title":"Medication adherence and persistence: a comprehensive review","volume":"22","author":"Krueger","year":"2005","journal-title":"Adv Ther"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa016\/31799204\/ofaa016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/2\/ofaa016\/32525953\/ofaa016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/2\/ofaa016\/32525953\/ofaa016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T18:59:09Z","timestamp":1665428349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa016\/5700872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,12]]},"references-count":179,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa016","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2020,1,12]]},"article-number":"ofaa016"}}